GenVec, Inc. (NASDAQ:GNVC) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item3.01.

On May 16, 2017, GenVec, Inc. (the Company) received a notice
from The NASDAQ Stock Market LLC (NASDAQ) that the Company is not
in compliance with NASDAQs Listing Rule 5550(b)(1) because it has
not maintained a minimum of $2.5 million in stockholders equity.
The notification of noncompliance has no immediate effect on the
listing or trading of the Companys common stock on NASDAQ under
the symbol GNVC.

to the NASDAQ Listing Rules, the Company has 45 days, or until
June 30, 2017, to submit a plan to regain compliance with the
minimum stockholders equity requirement. If the plan is accepted,
the Company may be granted up to 180 calendar days from May 16,
2017 to evidence compliance.

About GenVec, Inc. (NASDAQ:GNVC)

GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company’s lead product candidate is CGF166. The Company’s vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

GenVec, Inc. (NASDAQ:GNVC) Recent Trading Information

GenVec, Inc. (NASDAQ:GNVC) closed its last trading session up +0.15 at 7.50 with 21,675 shares trading hands.